D-0894-2022 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0894-2022 was initiated by Direct Rx on May 11, 2022 and is designated Class II. Reason for recall: CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits . The recall status is terminated (terminated Dec 2, 2022). Affected quantity: 6 bottles.

Recall Details

Product Type
Drugs
Report Date
Jun 1, 2022
Initiation Date
May 11, 2022
Termination Date
Dec 2, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
6 bottles

Product Description

Losartan Pot/HCTZ 50/12.5 mg 90 Tabs NDC 72189-297-90 Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg. For Macleods Pharma USA, Inc. Plainsboro, NJ 08540

Reason for Recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits .

Distribution Pattern

FL

Code Information

Lots: 19NO2108 Exp. 1/31/25; 19NO2114 Exp. 1/31/25; 22NO2126 Exp. 1/31/25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0894-2022
openFDA file date
Oct 23, 2026
Loaded by RegDataLab
Oct 26, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.